<DOC>
	<DOCNO>NCT01444352</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , immunogenicity investigational pneumococcal vaccine healthy adult volunteer . Primary Objective : - To evaluate safety tolerability investigational pneumococcal vaccine . Observational Objective : - To evaluate immunogenicity investigational Pneumococcal vaccine .</brief_summary>
	<brief_title>Study Investigational Pneumococcal Vaccine Three Dose Levels Healthy Adults</brief_title>
	<detailed_description>An initial cohort 10 participant receive single dose investigational pneumococcal vaccine . After safety assessment cohort 24-hour in-unit observation period , additional cohort receive two injection study vaccine 30 day apart , three dose level , ascend dos cohort , pending safety review dose level . All participant monitor safety 30 day vaccination .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Pneumonia , Pneumococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 18 50 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure Subject healthy , determined medical history physical examination For woman childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination 4 week last vaccination . History anaphylactic reaction asthma Unknown pregnancy positive serum/urine pregnancy test Currently breastfeed child Chronic illness , opinion investigator , stage could interfere trial conduct completion Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine 4 week precede first trial vaccination , except pandemic influenza vaccination may receive least two week study vaccine Planned receipt vaccine 4 week follow trial vaccination , except pandemic influenza vaccination event local national immunization program Known seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C Laboratory confirmed/selfreported thrombocytopenia contraindicate intramuscular ( IM ) vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Identified study site employee involve protocol may direct access trialrelated data Previous vaccination pneumococcal disease ( previous 5 year ) History pneumococcal infection ( confirm either clinically , serologically , microbiologically ) within 5 year At high risk pneumococcal infection trial Living household child &lt; 5 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pneumococcal infection</keyword>
	<keyword>Streptococcus pneumoniae Infections</keyword>
	<keyword>Pneumococcal Vaccines</keyword>
</DOC>